Cellular immunity after alemtuzumab

Recruiting

• Conditions: G35; Multiple sclerosis

• Registration Number: DRKS00011205
• Lead Sponsor: niversitätsklinikum Köln

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Multiple Sclerosis patients starting therapy with alemtuzumab

Exclusion Criteria

revocation of consent and underage patients

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Analysis of innate immune cells and inflammatory mediators after Alemtuzumab therapy <br>(primary endpoint: macrophage populations, macrophage polarizations with immunohistochemistry and flow cytomerty,<br>

Secondary Outcome Measures

Name	Time	Method
secondary endpoint: inflammatory parameters and mediators in the blood)<br>